|
1）Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011; 32: 63-71
|
|
|
|
2）Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011; 91: 733-94
|
|
|
|
|
|
3）Gorboulev V, Schürmann A, Vallon V, et al. Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012; 61: 187-96
|
|
|
|
|
|
4）Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011; 22: 104-12
|
|
|
|
|
|
5）Hediger MA, Coady MJ, Ikeda TS, et al. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987; 330: 379-81
|
|
|
|
|
|
6）Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na＋/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994; 93: 397-404
|
|
|
|
|
|
7）Ehrenkranz JR, Lewis NG, Kahn CR, et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005; 21: 31-8
|
|
|
|
|
|
8）Rossetti L, Shulman GI, Zawalich W, et al. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987; 80: 1037-44
|
|
|
|
|
|
9）Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987; 79: 1510-5
|
|
|
|
|
|
10）Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999; 48: 1794-800
|
|
|
|
|
|
11）Tsujihara K, Hongu M, Saito K, et al. Na+-glucose cotransporter (SGLT）inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4,-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem. 1999; 42: 5311-24
|
|
|
|
|
|
12）Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010; 1: 57-92
|
|
|
|
|
|
13）Banerjee SK, McGaffin KR, Pastor-Soler NM, et al. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009; 84: 111-8
|
|
|
|
|
|
14）Ramratnam M, Sharma RK, D,Auria S, et al. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1）attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc. 2014; 3. pii: e000899. doi: 10.1161/JAHA.114.000899
|
|
|
|
|
|
15）Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013; 36: 2154-61
|
|
|
|
|
|
16）Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013; 62: 3324-8
|
|
|
|
|
|
17）Cefalu WT. Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest. 2014; 124: 485-7
|
|
|
|
|
|
18）Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124: 499-508
|
|
|
|
|
|
19）Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014; 124: 509-14
|
|
|
|
|
|
20）Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005; 54: 3427-34
|
|
|
|
|
|
21）Tabatabai NM, Sharma M, Blumenthal SS, et al. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract. 2009; 83: e27-30
|
|
|
|
|
|
22）DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013; 36: 3169-76
|
|
|
|
|
|
23）Freitas HS, Anhê GF, Melo KF, et al. Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology. 2008; 149: 717-24
|
|
|
|
|
|
24）Pontoglio M, Prié D, Cheret C, et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000; 1: 359-65
|
|
|
|
|
|
25）Arakawa K, Ishihara T, Oku A, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001; 132: 578-86
|
|
|
|
|
|
26）Tahara A, Kurosaki E, Yokono M, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012; 385: 423-36
|
|
|
|
|
|
27）Kojima N, Williams JM, Takahashi T, et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther. 2013; 345: 464-72
|
|
|
|
|
|
28）Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129: 587-97
|
|
|
|
|
|
29）Cherney DZ, Perkins BA. Sodium-glucose co-transporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Can J Diabetes. 2014; 38: 356-63
|
|
|
|
|
|
30）DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012; 14: 5-14
|
|
|
|
|
|
31）Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012; 61: 2199-204
|
|
|
|
|